5353 Delveinsight 1

Neoantigen-based-Personalized-Cancer-Therapeutic-Vaccines

DelveInsight’s ‘Neoantigen based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast by 2035 report provides an in-depth understanding of Neoantigen based Personalized Cancer therapeutic Vaccines & the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some key facts of Neoantigen-based Personalized Cancer Therapeutic Vaccines Market are:

  • Expected launch of potential therapeutic Neoantigen-based Personalized Cancer Therapeutic Vaccines may push the  growth of the market size in the future, further assisted by an increase in the diagnosed incident population of various cancer indications along with technological advancements in treatment options, which makes it clear that the upcoming cancer vaccine is majorly expected to soar the overall therapeutic market in the oncology sector by acting as an adjuvant therapy to the already existing SOC (Standard of care therapies).
  • In terms of the Oncology indications, the most promising vaccine candidates in the pipeline under different stages of investigations by prominent key players are Gradalis (Ewing Sarcoma, Ovarian Cancer, melanoma), OSE Immunotherapeutics (NSCLC), and others.
  • Neoantigen based cancer vaccines also target several other indications such as Colorectal Cancer, Bone Cancer, Pancreatic Ductal Adenocarcinoma, Urothelial Carcinoma, Cutaneous Melanoma, Renal Cell Carcinoma, and others, each with their respective sub-types.
  • DelveInsight estimates that NSCLC shall account for 36.7% of Neoantigen-based personalized cancer therapeutic vaccines market share by 2035 in the United States in the 7MM.
  • DelveInsight estimates that Brain and Bone cancer will occupy the lowest market share in the overall Neoantigen Cancer Vaccine market.
  • Melanoma and Bladder cancer also account for a high market share but not as high as NSCLC in the Neoantigen Cancer Vaccine market in the 7 MM countries.

 

Request Sample Report To gain more insights : https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

List of Indications Covered:

  • Lung Cancer
  • Liver Cancer
  • Ovarian
  • Bladder
  • Melanoma
  • Colorectal
  • Brain
  • Renal Cell Carcinoma
  • Bone Cancer
  • Pancreatic Ductal Adenocarcinoma

 

Scope of the Neoantigen-based Personalized Cancer therapeutic Vaccines Report:

  • This report provides an Overview of several construction approaches for Neoantigen based Personalized Cancer therapeutic Vaccines, including comprehensive chapters for marketed products & emerging therapies.
  • Pipeline analysis across various stages of development (Phase III and Phase II), other emerging trends, & comparative analysis of pipeline products with complete clinical profiles, key cross-competition, launch date, along with product development activities.
  • The detailed market size of Neoantigen based Personalized Cancer therapeutic Vaccines, covering the US, EU5 (Germany, Spain, France, Italy, and United Kingdom), and Japan by 2035

 

Request Sample Report To gain more insights : https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

Cancer therapeutic Vaccines use weakened or killed bacteria ,viruses, or other germs to start an immune response in the body. These vaccines are designed to work similarly, teaching the immune system to recognize, attack, and destroy cancer cells. Neoantigen based Personalized Cancer therapeutic Vaccines allow the immune system to remember cancer cells as foreign, & therefore, get the immune system to counter the cancer cells. Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the immune system of the body to fight cancer.

The pipeline of Neoantigen based Personalized Cancer therapeutic Vaccines appears to be very promising with the availability of vaccines in different phases of development. The report offers in-depth analysis about 10+ Active Players & the Expected launch of 15+ potential Neoantigen based Personalized Cancer therapeutic Vaccines. There are various key players robustly involved in developing potential products such as Gradalis (Vigil), OSE Immunotherapeutics (Tedopi), Genocea (GEN-009), Immunitor (Hepko-V5), Gritstone Oncology (GRANITE (GRT-C901) + SLATE (GRT- R902)), Targovax (TG01 Vaccine), Hangzhou Neoantigen Therapeutics (iNeo-Vac-P01), Neon Therapeutics (NEO-PV-01) along with many more.

Request Sample Report To gain more insights : https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

Neoantigen-Based Personalized Cancer Therapeutic Vaccines covered in the report are:-

  • Vigil
  • iNeo-Vac-P01
  • NEO-PV-01
  • Tedopi (OSE2101)
  • Hepko-V5
  • GRANITE (GRT-C901) + SLATE (GRT-R902)
  • GEN-009
  • TG01 Vaccine
  • And many others

 

Key Neoantigen-Based Personalized Cancer Therapeutic Vaccine Players covered in the report are:-

  • Gradalis
  • OSE Immunotherapeutics
  • Immunitor
  • Gristone Oncology
  • Genocea
  • Targovax
  • Hangzhou Neoantigen Therapeutics
  • Neon Therapeutics
  • And many others

 

Request Sample Report To gain more insights : https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

Table of Contents

  1. Key Insight 
  2. Neoantigen based Personalized Cancer therapeutic Vaccines Market Overview at a Glance
  3. Neoantigen based Personalized Cancer therapeutic Vaccines Disease Background and Overview
  4. Neoantigen based Personalized Cancer therapeutic Vaccines Marketed Vaccines
  • Traditional-Conventional Cancer Vaccines
  • Provenge(Sipuleucel-T): Sanpower Group/Dendreon Corporation
  1. Neoantigen based Personalized Cancer therapeutic Emerging Vaccines 
  • Vigil: Gradalis
  • Tedopi (OSE2101): OSE Immunotherapeutics
  • Hepko-V5: Immunitor
  • TG01 Vaccine: Targovax
  • iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics
  • NEO-PV-01: Neon Therapeutics
  • GRANITE (GRT-C901) + SLATE (GRT-R902): Gristone Oncology
  • GEN-009: Genocea
  1. Therapeutic Assessment
  2. Comparison of Neoantigen based Personalized Cancer therapeutic Vaccines by Technology
  3. Attribute Analysis of Neoantigen- based Personalized Cancer therapeutic Vaccines
  4. Neoantigen based Personalized Cancer therapeutic Vaccines 7MM Analysis
  5. Case Reports
  6. SWOT Analysis for Neoantigen based Personalized Cancer therapeutic Vaccines
  7. Limitations of the cancer treatment vaccines
  8. Appendix
  9. Neoantigen based Personalized Cancer therapeutic Vaccines Report Methodology
  10. DelveInsight’s Capabilities
  11. Disclaimer

 

Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

 

Related Reports:

  1. ICOS-Next Generation Immunotherapy – Competitive Landscape and Market Forecast – 2035
  2. LAG-3-Next Generation Immunotherapy- Competitive Landscape and Market Forecast–2035
  3. TIM-3-Next Generation Immunotherapy – Competitive Landscape and Market Forecast – 2035

 

Latest Blogs:

 

Other Links:

 

About DelveInsight

DelveInsight is a leading Business Consulting and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Tags: Neoantigen-Based Personalized Cancer Therapeutic Vaccines, Cancer therapeutic vaccine, Vaccines Market, cancer, Neoantigen-Based Cancer Therapeutic Vaccines

Contact Information:

Ankit Nigam
[email protected]
+1(919)321-6187